论文部分内容阅读
作者对特发性弥漫性系膜增殖性肾小球肾炎(DPGN)用三联疗法——环磷酰胺,潘生丁和华法令联合治疗,并进行为期3年的前瞻性对照研究。所有病人都作经皮穿刺肾活检。按照肾功能及肾小球恶化程度配对地分为治疗组与对照组各52例,完成此项观察者分别为39例与34例,其中 IgA 肾炎分别为27例与21例。治疗组有肾病综合征5例,对照组2例(其余均未达到肾病综合征程度)。肾功能损害治疗组3例,对照组无。治疗组给予环磷酰胺1.5mg/kg/d 治疗6个月,潘生丁300mg/d 治疗36个月,华法令1.5～3mg/d(平均2.4±0.5mg/d;维持凝血试验在30～50%)36个月。并给予降压和利尿治疗.对照组病人则仅用降压药和利尿药。病情稳定的病人3个月复诊1次,每6个月进行一次尿镜检,血清肌酐
The authors treated a combination of cyclophosphamide, dipyridamole and warfarin for idiopathic diffuse mesangial proliferative glomerulonephritis (DPGN) with a 3-year prospective controlled study. All patients underwent percutaneous renal biopsy. In accordance with the degree of renal function and glomerular deterioration were paired into treatment group and control group, 52 cases completed the observation were 39 cases and 34 cases, of which IgA nephritis were 27 cases and 21 cases. The treatment group had nephrotic syndrome in 5 cases and control group in 2 cases (the others did not reach nephrotic syndrome). 3 cases of renal dysfunction group, the control group without. Treatment groups were given cyclophosphamide 1.5mg / kg / d for 6 months, dipyridamole 300mg / d for 36 months, warfarin 1.5-3mg / d (average 2.4 ± 0.5mg / d; to maintain the coagulation test in 30 to 50% ) 36 months. And given antihypertensive and diuretic treatment.The control group of patients only antihypertensive drugs and diuretics. Patients with stable disease referral 1 3 months, once every 6 months for urinalysis, serum creatinine